Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations

Albe-Fessard, 1967, Sur les relations entre la substance noire et le noyau caudé, J. Physiol. (Paris), 59, 324 Alvord, 1968, The pathology of Parkinsonism, Vol. 1, 1152 Andén, 1963, On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorimetric method, Life Sci., 2, 448, 10.1016/0024-3205(63)90132-2 Andén, 1964, Demonstration and mapping out of nigro-neostriatal dopamine neurons, Life Sci., 3, 523, 10.1016/0024-3205(64)90161-4 Andén, 1966, Ascending monoamine neurons to the telencephalon and diencephalon, Acta physiol. scand., 67, 313, 10.1111/j.1748-1716.1966.tb03318.x Andrews, 1970, Striatonigral degeneration, Arch. Neurol. (Chic.), 23, 319, 10.1001/archneur.1970.00480280033004 Arendt, 1956, Gliafaserfärbung nach Kanzler, Dtsch. Z. Nervenheilk., 175, 50, 10.1007/BF00218035 Barbeau, 1969, l-dopa therapy in Parkinson's disease, Canad. med. Ass. J., 101, 791 Barbeau, 1962, Les catécholamines dans la maladie de Parkinson, 247 Bédard, 1969, The nigrostriatal pathway, Exp. Neurol., 25, 365, 10.1016/0014-4886(69)90131-9 Bernheimer, 1964, Distribution of homovanillic acid in the human brain, Nature (Lond), 204, 587, 10.1038/204587b0 Bernheimer, 1965, Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels, Klin. Wschr., 43, 711, 10.1007/BF01707066 Bernheimer, 1973, Brain amines in Huntington's chorea, Vol. 1, 525 Bernheimer, 1961, Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom, Klin. Wschr., 39, 1056, 10.1007/BF01487648 Bernheimer, 1963, Zur Biochemie des Parkinsonsyndroms des Menschen, Klin. Wschr., 41, 564, 10.1007/BF01490014 Bertler, 1961, Occurrence and localization of catecholamines in the human brain, Acta physiol. scand., 51, 97, 10.1111/j.1748-1716.1961.tb02118.x Bertler, 1959, Occurrence and distribution of dopamine in brain and other tissues, Experientia (Basel), 15, 10, 10.1007/BF02157069 Birkmayer, 1970, Failures in l-dopa therapy, 12 Birkmayer, 1961, Der l-Dioxyphenylalanin (=l-Dopa)- Effekt bei der Parkinson-Akinese, Wien. klin. Wschr., 73, 787 Birkmayer, 1962, Der l-Dioxyphenylalanin (=l-Dopa)-effekt beim Parkinson-Syndrom des Menschen, Arch. Psychiat. Nervenkr., 203, 560, 10.1007/BF00343235 Bruyn, 1968, Huntington's chorea, Vol. 6, 298 Carpenter, 1972, Nigrostriatal and nigrothalamic fibers in the Rhesus monkey, J. comp. Neurol., 144, 93, 10.1002/cne.901440105 Connor, 1968, Caudate unit responses to nigral stimuli: evidence for a possible nigro-striatal pathway, Science, 160, 899, 10.1126/science.160.3830.899 Connor, 1970, Caudate nucleus neurons: correlation of the effects of substantia nigra stimulation with iontophoretic dopamine, J. Physiol. (Lond.), 208, 691, 10.1113/jphysiol.1970.sp009143 Cotzias, 1969, Modification of Parkinsonism, New Engl. J. Med., 280, 337, 10.1056/NEJM196902132800701 Cotzias, 1967, Aromatic amino acids and modification of Parkinsonism, New Eng. J. Med., 276, 374, 10.1056/NEJM196702162760703 Dahlström, 1964, Evidence for the existence of monoamine-containing neurons in the central nervous system, Part 1 (Demonstration of monoamines in the cell bodies of brain stem neurons), Acta physiol. scand., 62, 1 Davidson, 1971, l-Dopa treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions, Experientia (Basel), 27, 1048, 10.1007/BF02138873 Denny-Brown, 1962 Duvoisin, 1967, Cholinergic-anticholinergic antagonism in Parkinsonism, Arch. Neurol. (Chic.), 17, 124, 10.1001/archneur.1967.00470260014002 Duvoisin, 1966, Parkinsonism, 5 Earle, 1968, Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue, J. Neuropath. exp. Neurol., 27, 1, 10.1097/00005072-196801000-00001 Ehringer, 1960, Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems, Klin. Wschr., 38, 1236, 10.1007/BF01485901 Fahn, 1971, Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor, J. neurol. Sci., 14, 427, 10.1016/0022-510X(71)90178-X Faull, 1969, Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra, Exp. Neurol., 23, 332, 10.1016/0014-4886(69)90081-8 Forno, 1966, Pathology of Parkinsonism, J. Neurosurg., 24, 266 Forno, 1969, Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases), J. Amer. Geriat. Soc., 17, 557, 10.1111/j.1532-5415.1969.tb01316.x Frigyesi, 1967, Electrophysiological analysis of reciprocal caudato-nigral relations, Brain Research, 6, 440, 10.1016/0006-8993(67)90057-1 Fuxe, 1966, Studies on central monoamine neurons with special reference to the nigro-neostriatal dopamine neuron system, 123 Fuxe, 1964, Observations on the cellular localization of dopamine in the caudate nucleus of the rat, Z. Zellforsch., 63, 701, 10.1007/BF00339917 Gerstenbrand, 1963, Erfahrungen mit l-dopa in der Therapie des Parkinsonismus, Psychiat. et Neurol. (Basel), 146, 246, 10.1159/000128941 Goldstein, 1966, The effects of ventromedial tegmental lesions on the biosynthesis of catecholamines in the striatum, Life Sci., 5, 2171, 10.1016/0024-3205(66)90078-6 Goldstein, 1969, Studies of amines in the striatum in monkeys with nigral lesions, J. Neurochem., 16, 645, 10.1111/j.1471-4159.1969.tb06864.x Gottfries, 1965, The occurrence of homovanillic acid in human brain, Acta pharmacol. (Kbh.), 23, 36, 10.1111/j.1600-0773.1965.tb00347.x Greenfield, 1953, The brain-stem lesions in Parkinsonism, J. Neurol. Neurosurg. Psychiat., 16, 213, 10.1136/jnnp.16.4.213 Greer, 1971, Cerebral catecholamines after levodopa therapy, Neurology (Minneap.), 25, 461 Hallervorden, 1957, Paralysis agitans, Vol. 13, 900 Hassler, 1938, Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus, J. Psychol. Neurol. (Lpz.), 48, 387 Hassler, 1955, Extrapyramidal-motorische Syndrome und Erkrankungen, Vol. 4, 676 Hockman, 1971, Experimental midbrain lesions, Brain Research, 35, 613, 10.1016/0006-8993(71)90513-0 Hoehn, 1967, Parkinsonism, Neurology (Minneap.), 427, 10.1212/WNL.17.5.427 Hökfelt, 1969, Electron and fluorescent microscopic studies on the nucleus caudatus putamen of the rat after unilateral lesions of ascending nigro-neostriatal dopamine neurons, Acta physiol. scand., 76, 415, 10.1111/j.1748-1716.1969.tb04488.x Hornykiewicz, 1963, Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen, Wien. klin. Wschr., 73, 309 Hornykiewicz, 1964, Zur Frage des Verlaufes dopaminerger Neurone im Gehirn des Menschen, Wien. klin. Wschr., 75, 834 Hornykiewicz, 1966, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev., 18, 925 Hornykiewicz, 1972, Dopamine and its physiological significance in brain function, Vol. 6, 367 Hornykiewicz, 1972, Neurochemistry of Parkinsonism, Vol. 7, 465 Hornykiewicz, 1967, On the course of the nigro-striatal dopamine neurons in the human brain, Vol. 1, 255 Hornykiewicz, 1968, Homovanillic acid in different regions of the human brain, Brain Research, 11, 667, 10.1016/0006-8993(68)90154-6 Jellinger, 1968, Neuroaxonale Dystrophie, Verhandl. dtsch. Ges. Path., 52, 92 Jellinger, 1968, Striato-nigrale Degeneration, Acta neuropath. (Berl.), 10, 252, 10.1007/BF00687726 Jellinger, 1971, Die ZNS-Veränderungen bei den olivo-ponto-cerebellaren Atrophien, Z. Neurol. (Berl.), 199, 192 Kemp, 1971, The site of termination of afferent fibres in the caudate nucleus, Phil. Trans. roy. Soc. (Lond.) B., 262, 413, 10.1098/rstb.1971.0104 Klaue, 1940, Die Parkinsonsche Krankheit (Paralysis agitans) und postencephalitischer Parkinsonismus, Arch. Psychiat. Nervenkr., 111, 257, 10.1007/BF01813986 Klawans, 1970, A pharmacological analysis of Huntington's chorea, Europ. Neurol., 4, 148, 10.1159/000114017 Lloyd, 1970, Parkinson's disease, Science, 170, 1212, 10.1126/science.170.3963.1212 Lloyd, 1972, Occurrence and distribution of aromatic l-amino acid (l-dopa) decarboxylase in the human brain, J. Neurochem., 19, 1549, 10.1111/j.1471-4159.1972.tb05099.x McLennan, 1963 McLennan, 1965, The release of dopamine from the putamen, Experientia (Basel), 21, 725, 10.1007/BF02138500 Mittenecker, 1964 Moore, 1971, Anatomical and chemical studies of a nigro-neostriatal projection in the cat, Brain Research, 30, 119, 10.1016/0006-8993(71)90009-6 Nauta, 1966, Projections of the lentiform nucleus in the monkey, Brain Research, 1, 3, 10.1016/0006-8993(66)90103-X Neff, 1969, Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys, Experientia (Basel), 25, 1140, 10.1007/BF01900234 Neumayer, 1971, Kombination von M. Parkinson mit anderen zentralnervösen Krankheitzen, Z. Neurol. (Berl.), 199, 306 Olivier, 1970, Cholesterasic striatopallidal and striatonigral efferents in the cat and the monkey, Brain Research, 18, 273, 10.1016/0006-8993(70)90328-8 Orthner, 1972, Maschinelle Zählung der pigmentierten Neurone in der Substantia nigra beim Parkinsonsyndrom im Vergleich zur Norm Pakkenberg, 1965, The number of nerve cells in the substantia nigra in paralysis agitans, Acta neuropath. (Berl.), 5, 320, 10.1007/BF00686528 Parent, 1969, The medial forebrain bundle (MFB) and ascending monoaminergic pathways in the cat, Canad. J. Physiol. Pharmacol., 47, 781, 10.1139/y69-131 Parent, 1969, Effect of interrupting the hypothalamic nervous connection on the norepinephrine and serotonin content in the hypothalamus, Exp. Neurol., 23, 67, 10.1016/0014-4886(69)90034-X Pentschew, 1963, Experimental manganese encephalopathy in monkeys, J. Neuropath. exp. Neurol., 22, 488, 10.1097/00005072-196307000-00010 Poirier, 1964, Influence du locus niger sur la concentration des catécholamines du striatum, J. Physiol. (Paris), 56, 426 Poirier, 1965, Influence of the substantia nigra on the catecholamine content of the striatum, Brain, 88, 181, 10.1093/brain/88.1.181 Poirier, 1967, Effect of amine precursors on the concentration of striatal dopamine and serotonin in cats with and without unilateral brain stem lesions, Brain Research, 6, 654, 10.1016/0006-8993(67)90123-0 Poirier, 1969, The effect of brain stem lesions on tyrosine and tryptopham hydroxylases in various structures of the telencephalon of the cat, Brain Research, 14, 147, 10.1016/0006-8993(69)90036-5 Poirier, 1967, Effect of brain lesions on striatal amines in the cat, Arch. Neurol. (Chic.), 17, 604, 10.1001/archneur.1967.00470300043008 Portig, 1969, Release into the cerebral ventricles of substances with possible transmitter function in the caudate nucleus, J. Physiol. (Lond.), 204, 687, 10.1113/jphysiol.1969.sp008939 Riddell, 1971, The release in vivo of dopamine synthesized from labelled precursors in the caudate nucleus of the cat, J. Neurochem., 18, 989, 10.1111/j.1471-4159.1971.tb12029.x Rinne, 1971, Effect of l-dopa on brain monoamines and their metabolites in Parkinson's disease, Life Sci., 10, 549, 10.1016/0024-3205(71)90040-3 Sano, 1959, Distribution of catechol compounds in human brain, Biochim. biophys. Acta (Amst.), 32, 586, 10.1016/0006-3002(59)90652-3 Seitelberger, 1966, Die Hallervorden-Spatzsche Krankheit, Nervenarzt, 37, 482 Seitelberger, 1969, Heterogenous system degeneration, Acta neurol. (Bari), 24, 276 Seitelberger, 1964, Verhalten des Dopamins (=3-Hydroxytyramin) im Nucleus caudatus nach elektrischer Koagulation des Globus pallidus, Naturwissenschaften, 51, 314, 10.1007/BF00624184 Selby, 1968, Parkinson's disease, 173 Sharman, 1963, A fluorimetric method for the estimation of 4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid) and its identification in brain tissue, Brit. J. Pharmacol., 20, 204 Sharman, 1967, Homovanillic acid and dihydroxyphenylacetic acid in the striatum of monkeys with brain lesions, Canad. J. Physiol., 45, 57, 10.1139/y67-006 Sharpe, 1973, Striatonigral degeneration, J. neurol. Sci., 19, 275, 10.1016/0022-510X(73)90091-9 Siegfried, 1968 Sluga, 1966, Zur Ultrastruktur des Striatums, Wien. Z. Nervenheilk., 23, 17 Sourkes, 1961, Determination of catecholamines and catecholamino acids by differential spectrophotofluorimetry, Vol. 9, 147 Sourkes, 1966, Neurochemical bases of tremor and other disorders of movement, Canad. med. Ass. J., 94, 53 Spatz, 1938, Die “systematischen Atrophien”, Arch. Psychiat. Nervenkr., 108, 1, 10.1007/BF01825872 Stadler, 1936, Zur Histopathologie des Gehirns bei Manganvergiftung, Zbl. ges. Neurol. Psychiat., 154, 63 Steele, 1964, Progressive supranuclear palsy, Arch. Neurol. (Chic.), 10, 333, 10.1001/archneur.1964.00460160003001 Szabo, 1962, Topical distribution of the striatal efferents in the monkey, Exp. Neurol., 5, 21, 10.1016/0014-4886(62)90067-5 Szabo, 1967, The efferent projections of the putamen in the monkey, Exp. Neurol., 19, 463, 10.1016/0014-4886(67)90166-5 Udenfriend, 1958, Assay of serotonin and related metabolites, enzymes and drugs, Vol. 6, 95 Vogt, 1937, Sitz und Wesen der Krankheiten im Lichte der topistischen Gehirnforschung und des Variierens der Tiere, J. Psychol. Neurol. (Lpz.), 47, 237 Von Voigtlander, 1971, Nigro-striatal pathway: stimulation-evoked release of [3H]dopamine from caudate nucleus, Brain Research, 35, 580, 10.1016/0006-8993(71)90506-3 Von Voigtlander, 1971, The release of 3H-dopamine from cat brain following electrical stimulation of the substantia nigra and caudate nucleus, Neuropharmacology, 10, 733, 10.1016/0028-3908(71)90088-8 Voneida, 1960, An experimental study of the course and destination of fibers arising in the head of the caudate nucleus in the cat and monkey, J. comp. Neurol., 115, 75, 10.1002/cne.901150107 Weil-Malherbe, 1961, The fluorimetric estimation of catecholamines, Vol. 9, 130 Werman, 1966, Criteria for identification of a central nervous system transmitter, Comp. Biochem. Physiol., 18, 745, 10.1016/0010-406X(66)90209-X Wood, 1969, Dopamine sites in the basal ganglia, Texas Rep. Biol. Med., 27, 1077 Yahr, 1968, l-DOPA (l-3,4-dihydroxyphenylalanine): its clinical effects in parkinsonism, Trans. Amer. neurol. Ass., 93, 56 York, 1970, Possible dopaminergic pathway from substantia nigra to putamen, Brain Research, 20, 233, 10.1016/0006-8993(70)90291-X